億緯鋰能(300014.SZ):擬向貝特瑞(四川)新材料增資8.84億元
格隆匯9月27日丨億緯鋰能(300014.SZ)公佈,公司擬與貝特瑞及其子公司貝特瑞(四川)新材料科技有限公司(以下簡稱“標的公司”)簽訂《關於貝特瑞(四川)新材料科技有限公司之增資合同書》,公司以1元每元註冊資本的價格向標的公司增資8.84億元,持有標的公司40%的股權;貝特瑞向標的公司增資至13.26億元,持有標的公司60%的股權。
公司及貝特瑞計劃在四川省宜賓市屏山縣屏山鎮宋家壩產業園區合資建設鋰電池負極材料一體化基地,實施主體為標的公司。建設目標為在2024年6月30日前形成年產10萬噸鋰電池負極材料一體化產能,產能優先供給公司,後續根據市場情況確定是否繼續增加產能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.